NEWS - Bournemouth, UK – 12th January 2017: Solentim, the leader in Cell Line Development instrumentation, announce another record year of sales.
"We have seen worldwide order values increase by over 80% year-on-year for calendar year 2016, and now nine out of the Top Ten Pharma have purchased Cell Metric for their biotherapeutic cell line development", commented Aaron Figg, Director.
During the past year Solentim has continued its track record of investing in new product development and enhancements including the launch of the 'Fluorescence for Clonality' application for process QC and the integration of the Cell Metric instrumentation into robotic workcells to support ultra-high throughput, fully automated customer workflows. Additionally, the company's direct sales team was extended in Central Europe and there has been continued major investment in R&D to support the new product pipeline which will be introduced at major international conferences during 2017. The company also moved to a larger site during the year in order to accommodate increased production demands.
Mr Figg concluded, "Another year of solid financial performance further consolidates and strengthens our position as a company and as a long-term partner for our customers. We look forward to an exciting 2017 and introducing a range of additional new products for cell line development."